Theorems and implications of a model-independent elimination/distribution function decomposition of linear and some nonlinear drug dispositions. III. Peripheral bioavailahility and distribution time concepts applied to the evaluation of distribution kinetics
- 1 June 1987
- journal article
- research article
- Published by Springer Nature in Journal of Pharmacokinetics and Biopharmaceutics
- Vol. 15 (3) , 281-304
- https://doi.org/10.1007/bf01066323
Abstract
Disposition decomposition analysis (DDA) is applied to evaluate the rate and extent of drug delivery from the sampling compartment to the peripheral system, i.e., peripheral bioavailability. Four parameters are introduced which are useful in quantifying peripheral bioavailability. The compounded peripheral bioavailability, Fcomp,is the ratio between the total compounded amount of drug transferred to the peripheral system and the injected dose, D.The AUCperipheral bioavailability, FAUC,is the ratio between the area under the amount vs.time curves for the peripheral system and the sampling compartment. The distribution time td,is the time following an i.v. bolus at which the net transfer of drug to the peripheral system reverses in direction. The maximum peripheral bioavailability, Fmax,is the maximum fraction of an i.v. bolus dose that is present in the peripheral system at any one time. Equations are derived which permit estimation of those parameters from drug concentrations in the sampling compartment. Simple algorithms and a computer program are provided for estimating Fcomp, FAUC, td, Fmax,and other parameters relevant to DDA for drugs that exhibit a linear polyexponential bolus response. Estimates of Ecomp, FAUC, td,are presented for several drugs.This publication has 38 references indexed in Scilit:
- Theorems and implications of a model independent elimination/distribution function decomposition of linear and some nonlinear drug dispositions. I. Derivations and theoretical analysisJournal of Pharmacokinetics and Biopharmaceutics, 1984
- Pharmacokinetics of quinidine and three of its metabolites in manJournal of Pharmacokinetics and Biopharmaceutics, 1984
- The pharmacokinetics of furazlocillin in healthy humansJournal of Pharmacokinetics and Biopharmaceutics, 1983
- Pharmacokinetics of cefroxadin (CGP 9000) in manJournal of Pharmacokinetics and Biopharmaceutics, 1982
- Pharmacokinetics of bretylium in man after intravenous administrationJournal of Pharmacokinetics and Biopharmaceutics, 1980
- Disposition kinetics of ethambutol in manJournal of Pharmacokinetics and Biopharmaceutics, 1980
- Disposition of synthetic glucocorticoids I. Pharmacokinetics of dexamethasone in healthy adultsJournal of Pharmacokinetics and Biopharmaceutics, 1979
- Pharmacokinetics of propranolol in normal healthy volunteersJournal of Pharmacokinetics and Biopharmaceutics, 1977
- Pharmacokinetic and biopharmaceutic profile of chlordiazepoxide HCl in healthy subjects: Single-dose studies by the intravenous, intramuscular, and oral routesJournal of Pharmacokinetics and Biopharmaceutics, 1977
- Theoretical and computational basis for drug bioavailability determinations using pharmacological data. I. General considerations and proceduresJournal of Pharmacokinetics and Biopharmaceutics, 1976